Denali Financial Statements From 2010 to 2024

DNLI Stock  USD 15.56  0.55  3.41%   
Denali Therapeutics financial statements provide useful quarterly and yearly information to potential Denali Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Denali Therapeutics financial statements helps investors assess Denali Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Denali Therapeutics' valuation are summarized below:
Gross Profit
-250.3 M
Profit Margin
(0.44)
Market Capitalization
2.3 B
Enterprise Value Revenue
4.716
Revenue
330.5 M
We have found one hundred twenty available fundamental signals for Denali Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Denali Therapeutics prevailing fundamentals against the fundamentals between 2010 and 2024 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 2.2 B. Enterprise Value is estimated to decrease to about 2.1 B

Denali Therapeutics Total Revenue

347.06 Million

Check Denali Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Denali main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.6 M, Interest Expense of 8.6 M or Selling General Administrative of 54.3 M, as well as many exotic indicators such as Price To Sales Ratio of 8.47, Dividend Yield of 0.0 or PTB Ratio of 2.17. Denali financial statements analysis is a perfect complement when working with Denali Therapeutics Valuation or Volatility modules.
  
This module can also supplement Denali Therapeutics' financial leverage analysis and stock options assessment as well as various Denali Therapeutics Technical models . Check out the analysis of Denali Therapeutics Correlation against competitors.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

Denali Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets932.8 M1.2 B583.2 M
Slightly volatile
Other Current Liabilities31.3 M61.2 M19.8 M
Slightly volatile
Total Current Liabilities121.8 M78 M75.7 M
Slightly volatile
Other Liabilities937.4 K986.7 K31.3 M
Pretty Stable
Property Plant And Equipment Net52.4 M71.6 M33.1 M
Slightly volatile
Accounts Payable10 M9.5 M3.2 M
Slightly volatile
Cash194.5 M127.1 M129.3 M
Slightly volatile
Non Current Assets Total154.9 M89.8 M95.9 M
Slightly volatile
Non Currrent Assets Other17.4 M16.5 M4.9 M
Slightly volatile
Other Assets0.951.02.7 M
Slightly volatile
Cash And Short Term Investments757.9 MB474.2 M
Slightly volatile
Common Stock Total Equity1.5 M1.8 MM
Slightly volatile
Common Stock Shares Outstanding86.7 M137.4 M54.1 M
Slightly volatile
Liabilities And Stockholders Equity932.8 M1.2 B583.2 M
Slightly volatile
Non Current Liabilities Total42.7 M45 M72.7 M
Pretty Stable
Capital Surpluse1.9 B1.8 B718.5 M
Slightly volatile
Other Current Assets18.9 M26.9 M12.4 M
Slightly volatile
Other Stockholder Equity1.1 B2.1 B703.2 M
Slightly volatile
Total Liabilities220 M123 M152.1 M
Slightly volatile
Property Plant And Equipment Gross123.5 M117.6 M40.2 M
Slightly volatile
Preferred Stock Total Equity218.3 M401 M223.3 M
Slightly volatile
Total Current Assets778 M1.1 B487.4 M
Slightly volatile
Common Stock1.6 M1.7 MM
Slightly volatile
Property Plant Equipment44.6 M85.7 M31.4 M
Slightly volatile
Net Receivables3.8 M2.7 M2.4 M
Slightly volatile
Short Term Investments633.8 M907.4 M404.9 M
Slightly volatile
Non Current Liabilities Other414.1 K435.9 K25.9 M
Pretty Stable
Net Invested Capital879 MB648.9 M
Slightly volatile
Net Working Capital811.7 M986.2 M583 M
Slightly volatile
Current Deferred Revenue350.2 M333.6 M95.9 M
Slightly volatile
Deferred Long Term Liabilities4.7 M5.3 M5.7 M
Slightly volatile
Capital Stock1.7 M1.7 M1.4 M
Slightly volatile
Short Term Debt6.3 M7.3 M13.8 M
Slightly volatile
Short and Long Term Debt Total48.7 M52.2 M64.8 M
Slightly volatile
Capital Lease Obligations50 M52.2 M67.7 M
Slightly volatile

Denali Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization17.6 M16.7 M5.5 M
Slightly volatile
Selling General Administrative54.3 M103.4 M35 M
Slightly volatile
Other Operating Expenses269.3 M527.2 M170.4 M
Slightly volatile
Research Development215 M423.9 M135.4 M
Slightly volatile
Total Operating Expenses267.3 M510.5 M169.2 M
Slightly volatile
Net Interest Income47.3 M45 M10.2 M
Slightly volatile
Interest Income54.1 M51.5 M11.1 M
Slightly volatile
Reconciled Depreciation10.2 M18.6 M6.4 M
Slightly volatile
Non Operating Income Net Other7.8 M4.1 M9.1 M
Slightly volatile
Selling And Marketing Expenses13.4 M15.1 M16.4 M
Slightly volatile

Denali Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock16.5 M17.4 M77.1 M
Very volatile
Net BorrowingsM4.5 M4.9 M
Slightly volatile
Stock Based Compensation113.5 M108.1 M35 M
Slightly volatile
Other Cashflows From Financing Activities16.9 M17.8 M67.1 M
Very volatile
Depreciation17.6 M16.7 M5.5 M
Slightly volatile
Capital Expenditures9.3 M12.9 M6.7 M
Slightly volatile
Total Cash From Financing Activities16.9 M17.8 M132.8 M
Pretty Stable
End Period Cash Flow195.4 M127.1 M129.9 M
Slightly volatile
Change To Netincome114.6 M109.2 M35.8 M
Slightly volatile
Begin Period Cash Flow202.2 M218 M123.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.478.918925.5947
Slightly volatile
Days Sales Outstanding2.832.981617.4353
Slightly volatile
Invested Capital0.08320.05070.0544
Slightly volatile
Stock Based Compensation To Revenue0.630.32710.4352
Slightly volatile
EV To Sales8.268.692424.6741
Slightly volatile
Payables Turnover1.681.763863.4871
Slightly volatile
Sales General And Administrative To Revenue0.30.31270.4832
Slightly volatile
Research And Ddevelopement To Revenue1.221.28241.9415
Slightly volatile
Cash Per Share13.857.530811.8829
Very volatile
Days Payables Outstanding10720754.7053
Slightly volatile
Current Ratio15.0713.645912.4262
Very volatile
Receivables Turnover12912237.7786
Slightly volatile
Graham Number12.6913.360928.6331
Pretty Stable
Debt To Equity0.08320.05070.0544
Slightly volatile
Revenue Per Share2.532.40611.474
Pretty Stable
Interest Debt Per Share0.380.38030.3124
Slightly volatile
Debt To Assets0.06140.04530.0418
Slightly volatile
Days Of Payables Outstanding10720754.7053
Slightly volatile
Ebt Per Ebit1.050.73820.973
Pretty Stable
Long Term Debt To Capitalization0.07680.04180.1175
Slightly volatile
Total Debt To Capitalization0.07520.04820.0504
Slightly volatile
Debt Equity Ratio0.08320.05070.0544
Slightly volatile
Quick Ratio14.7413.300611.9671
Pretty Stable
Net Income Per E B T0.81.00020.9846
Slightly volatile
Cash Ratio1.551.62995.9008
Slightly volatile
Days Of Sales Outstanding2.832.981617.4353
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.171.03611.1137
Slightly volatile
Fixed Asset Turnover3.084.6144.0631
Slightly volatile
Debt Ratio0.06140.04530.0418
Slightly volatile
Price Sales Ratio8.478.918925.5947
Slightly volatile
Asset Turnover0.30.28640.1806
Very volatile

Denali Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.2 B2.9 B1.7 B
Slightly volatile
Enterprise Value2.1 B2.9 B1.6 B
Slightly volatile

Denali Fundamental Market Drivers

Cash And Short Term InvestmentsB

Denali Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Denali Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Denali Therapeutics income statement, its balance sheet, and the statement of cash flows. Denali Therapeutics investors use historical funamental indicators, such as Denali Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Denali Therapeutics investors may use each financial statement separately, they are all related. The changes in Denali Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Denali Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Denali Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Denali Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue333.6 M350.2 M
Total Revenue330.5 M347.1 M
Cost Of Revenue16.7 M15.9 M
Stock Based Compensation To Revenue 0.33  0.63 
Sales General And Administrative To Revenue 0.31  0.30 
Research And Ddevelopement To Revenue 1.28  1.22 
Capex To Revenue(0.04)(0.04)
Revenue Per Share 2.41  2.53 
Ebit Per Revenue(0.60)(0.62)

Pair Trading with Denali Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Denali Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Denali Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Denali Stock

  0.75VKTX Viking Therapeutics Potential GrowthPairCorr
  0.68ELEV Elevation Oncology Earnings Call This WeekPairCorr
  0.64ENVB Enveric Biosciences Financial Report 20th of May 2024 PairCorr
The ability to find closely correlated positions to Denali Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Denali Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Denali Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Denali Therapeutics to buy it.
The correlation of Denali Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Denali Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Denali Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Denali Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:
Check out the analysis of Denali Therapeutics Correlation against competitors.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.
You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.06)
Revenue Per Share
2.406
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.09)
Return On Equity
(0.14)
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.